Prof. PeptideProf. Peptide
Guide

How is NAD+ dosed?

Every completed human trial of NAD+ itself used intravenous administration — not the subcutaneous route Prof. Peptide’s own reconstitution calculator covers. This page reads each trial’s molecule and route directly, keeps NAD+ separate from its precursors NMN and NR, and states plainly where community IV dosing sits far above what was actually studied.

Topic: Reading which molecule and which route every NAD+ study actually used

Audience: Anyone comparing an NAD+ dose figure against what was actually studied, in which form and by which route

Reading time: 9–11 minutes

No approved product; every completed trial of NAD+ itself was intravenous

NAD+ has not been approved by the FDA, EMA, or any regulatory body. Every completed, published human trial of NAD+ itself found for this page used intravenous administration — a different route from the subcutaneous self-injection Prof. Peptide’s NAD+ calculator is scoped to. One trial with a genuine subcutaneous NAD+ arm is currently recruiting, with no results yet. Every figure on this page is a fact about a specific study — not a recommendation.

On this page
  1. 1.NAD+, NMN, and NR: one molecule and two precursors
  2. 2.What the trials administered — all of them IV
  3. 3.The subcutaneous gap: one recruiting trial, no completed one
  4. 4.Is there a community-reported dose, and how does it compare?
  5. 5.Regulatory position: absent from FDA's compounding lists, and NMN's separate history
  6. 6.Related pages
  7. 7.FAQ
  8. 8.References

NAD+, NMN, and NR: one molecule and two precursors

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in cellular energy metabolism. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors the body converts into NAD+ over time, rather than NAD+ itself. Several trials commonly cited in NAD+ discussions — including a landmark study establishing safe oral dosing in older adults — studied a precursor, not NAD+ directly. The NAD+ profile covers that broader precursor literature and the underlying biology in more depth; this page exists specifically to read the trials of NAD+ itself, state their route directly, and never present a precursor’s result as if it were one.

The evidence below is ordered the way the site’s own convention places it: trial data first, with molecule and route stated for each, then community-reported practice last, attributed and marked unverified.

What the trials administered — all of them IV

Three studies of NAD+ itself were found and re-pulled or re-read directly. Each is graded against Prof. Peptide’s standing citation convention — a claim is attributed when it resolves to a named, checkable source.

ChromaDex IV Tolerability Comparison — NAD+ vs. NR vs. Oral NR

NCT06382688

Molecule and route: NAD+ (nicotinamide adenine dinucleotide) and NR (nicotinamide riboside) — a direct head-to-head, not a precursor study alone.

UNKNOWN (per the registry's own status field); no results posted

Design: Two-part randomized, double-blind study in healthy adults. Study 1 included all four arms (37 participants); Study 2 included only the active NR and NAD+ arms, to further evaluate IV tolerability and comfort.

Arms: 53 participants total (actual, per the registry): 500 mg IV NAD+, 500 mg IV NR, 500 mg oral NR (Study 1 only), or IV placebo (saline).

Endpoint reported: No results have been posted to the registry and no peer-reviewed publication was found for this page.

Topline absent — a registered, real trial directly comparing IV NAD+ to IV and oral NR, but with no reported outcome of any kind as of this page's build.

Yu et al. 2026 — NAD+ for Heart Failure (Ischemic Cardiomyopathy)

Yu X, Xu J, Cao J, et al. Am J Cardiovasc Drugs. 2026;26(1):97–106. PMID 40954388. ChiCTR2200059169 (Chinese Clinical Trial Registry).

Molecule and route: NAD+ (nicotinamide adenine dinucleotide) itself, not a precursor.

Completed, peer-reviewed

Design: Single-center, prospective, randomized, placebo-controlled trial in 180 adults with ischemic cardiomyopathy (LVEF ≤45%, NYHA class II–III), alongside guideline-directed medical therapy.

Arms: Intravenous NAD+ 10 mg/day, or an equivalent placebo (5% glucose/normal saline), for 7 days.

Endpoint reported: Primary endpoint (LVEF change at 1 month): 45.44% (NAD+) versus 42.44% (placebo), p=0.024 — statistically significant. Secondary trends (not individually significant): lower NT-proBNP at day 7, fewer 6-month major adverse cardiac/cerebrovascular events, more NYHA functional-class improvement.

Adverse events reported: Not reported in detail in the abstract beyond the trial's safety framing; no specific adverse-event rate was stated for either arm.

Attributed — verbatim PubMed abstract read directly, peer-reviewed. Registered with China's own trial registry (ChiCTR), not a US NCT number — noted as such rather than implying a US registration that doesn't exist. The strongest human evidence for NAD+ itself found for this page.

Reyna et al. 2026 — Retrospective Real-World Tolerability, NAD+ vs. NR

Reyna K, Heinzen G, Patel N, et al. Front Aging. 2026;7:1652582. PMID 41704678.

Molecule and route: NAD+ (nicotinamide adenine dinucleotide) and NR (nicotinamide riboside), both by IV — a direct comparison.

Completed, peer-reviewed, retrospective (not a randomized trial)

Design: Retrospective review of electronic medical records from a commercial wellness clinic (RestoreLabs / Restore Hyperwellness), with 30-day follow-up.

Arms: 14 participants total: 6 received IV NAD+, 8 received IV NR — each 500 mg/day for 4 consecutive days.

Endpoint reported: Average infusion time: 97 minutes (NAD+) versus 37 minutes (NR) — NR roughly 60% faster. Exploratory metabolic biomarker outcomes were variable across both groups.

Adverse events reported: All 6 IV NAD+ participants reported moderate-to-severe gastrointestinal symptoms (abdominal cramping, nausea, vomiting, diarrhea), increased heart rate, throat pain, congestion, and chest pressure during infusion, resolving once the infusion ended. 5 of 8 NR participants reported milder tongue, jaw, and arm tingling and mild cramping; one had severe cramping coinciding with menstruation on day 2 but continued treatment.

Attributed — verbatim PubMed abstract read directly, peer-reviewed, but a retrospective chart review from a single commercial clinic, not a randomized controlled trial — a weaker design tier than Yu et al. 2026, reported as such.

The subcutaneous gap: one recruiting trial, no completed one

No completed, published human trial of subcutaneous NAD+ was found. One currently active trial does test it directly:

Absorption and Tolerability of Injectable Niagen®+ vs. NAD+ (Includes a Genuine Subcutaneous NAD+ Arm)

NCT06919328

RECRUITING (confirmed against the live ClinicalTrials.gov API on the date this page was built); no results yet

Design: Randomized study in healthy adults evaluating subjective effects and tolerability of NR and NAD+ across three injection routes.

Arms: 70 participants planned (estimated), across nine arms: NR via intramuscular injection, NR via subcutaneous injection, NR via IV push, NAD+ via intramuscular injection, NAD+ via subcutaneous injection, NAD+ via IV push, and three matching bacteriostatic-water placebo arms — each active arm dosed at 100 mg in 2 mL bacteriostatic water.

This is the one trial found that directly matches the route Prof. Peptide's own NAD+ calculator is scoped to (subcutaneous). It is currently recruiting, with no posted results — reported here as the closest available match to the calculator's own scope, not as completed evidence.

The NAD+ reconstitution calculator performs the arithmetic of converting a vial and reconstitution volume into syringe units for a given milligram figure, for the subcutaneous route specifically; it does not set a schedule and does not imply that route has completed trial support.

Is there a community-reported dose, and how does it compare?

Yes, and it varies by route. The NAD+ profile documents community IV clinic dosing at 250–1,000 mg per session (monthly to weekly), subcutaneous self-injection at 50–100 mg, and oral precursor dosing at 250–1,000 mg daily. These are reported here, below the trial evidence above, as observed practice attributed to where they circulate — not derived from any of the trials on this page.

The IV figure diverges clearly from what has actually been studied. Every completed trial of NAD+ itself used a dose at or below roughly 125 mg/day averaged (500 mg over 4 days in the retrospective tolerability pilot; 10 mg/day in the placebo-controlled heart-failure RCT) — both well below the 250–1,000 mg per session commonly marketed at IV clinics. No source was found deriving the clinic-marketed figure from either trial.

Regulatory position: absent from FDA’s compounding lists, and NMN’s separate history

NAD+ does not appear on FDA’s 503A/503B compounding safety-risk lists at all — checked directly.

“NAD,” “nicotinamide adenine dinucleotide,” “nicotinamide riboside,” and “nicotinamide mononucleotide” were each searched directly against FDA’s own bulk-substance safety-risk page. None appear in either the active Category 2 list or the “nominated but withdrawn” table — unlike BPC-157, TB-500, ipamorelin, and CJC-1295, none of these substances has been through FDA’s 503A/503B evaluation process at all, as far as this page could confirm.

NMN — a precursor, not NAD+ itself — has its own separate, unrelated regulatory history: FDA excluded it from the dietary-supplement definition in fall 2022, applying the drug-preclusion clause on the grounds that NMN had first been authorized for investigation as a new drug. FDA reversed that exclusion on September 29, 2025, following a citizen petition and litigation, and has since confirmed to individual companies that NMN can again be marketed as a dietary supplement. That history concerns NMN’s status as a supplement ingredient specifically, not any finding about NAD+’s own compounding eligibility, and this page keeps the two distinct.

FAQ

Is there an FDA-approved NAD+ product?
No. NAD+ has not been approved by the FDA, EMA, or any regulatory body as a drug for any indication. It is administered in wellness and functional-medicine clinics as an IV infusion, and sold as a research-grade subcutaneous, oral, or sublingual product by specialty vendors, outside any approval framework.
Do NAD+ trials use the same route Prof. Peptide's calculator covers?
No completed one does. Every published, completed human trial of NAD+ itself found for this page used intravenous administration. Prof. Peptide's NAD+ reconstitution calculator is scoped specifically to subcutaneous dosing, because the profile's own SC figures (50-100 mg) are a different order of magnitude from its IV figures (250-1000 mg). One currently recruiting trial, NCT06919328, does include a genuine subcutaneous NAD+ arm (100 mg via SQ injection) directly comparable to the calculator's own scope — but it has posted no results yet.
What dose did the NAD+ heart failure trial use?
Yu et al. 2026 (PMID 40954388) administered intravenous NAD+ at 10 mg per day for 7 days, in 180 adults with heart failure from ischemic cardiomyopathy, registered with the Chinese Clinical Trial Registry (ChiCTR2200059169), not a US ClinicalTrials.gov NCT number. At 1 month, the NAD+ group showed a significantly greater improvement in left ventricular ejection fraction than placebo (45.44% vs. 42.44%, p=0.024).
What adverse events were reported for IV NAD+?
Reyna et al. 2026 (PMID 41704678), a retrospective review of a commercial wellness clinic's records, reported that all 6 participants receiving IV NAD+ (500 mg/day for 4 days) experienced moderate-to-severe gastrointestinal symptoms, increased heart rate, and chest pressure during infusion — symptoms that resolved once each infusion ended. The comparison IV nicotinamide riboside (NR) group (n=8) reported milder tingling and cramping. Yu et al. 2026's larger RCT did not report a comparable rate of acute infusion-related symptoms in its abstract.
Are NMN and NR the same thing as NAD+?
No. NAD+ is the molecule itself. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors — the body converts them into NAD+ over time rather than receiving NAD+ directly. Several trials commonly cited in NAD+ discussions, including the landmark NR trial establishing safe oral dosing in older adults, studied a precursor, not NAD+ itself. This page states which molecule each cited study actually used and does not present a precursor's result as an NAD+ result.
How does the studied dose compare to what clinics market?
It sits well below it. Every studied NAD+-itself dose found for this page ranges from 10 mg/day (the heart-failure RCT) to 500 mg over 4 days, roughly 125 mg/day averaged (the retrospective tolerability pilot). The NAD+ profile's own community-practice section documents IV clinic dosing commonly marketed at 250-1000 mg per session — several times the daily rate in either trial. This divergence is reported directly, sourced to both the trials and the profile's own figures, not inferred.
What is NAD+'s FDA compounding status?
Checked directly against FDA's own 503A and 503B bulk-substance safety-risk pages: neither "NAD," "nicotinamide adenine dinucleotide," "nicotinamide riboside," nor "nicotinamide mononucleotide" appears on either list, in any category — active Category 2 or the withdrawn-nominations table. Separately, NMN (a precursor, not NAD+ itself) has its own distinct FDA history unrelated to compounding: FDA excluded it from the dietary-supplement definition in fall 2022 under the drug-preclusion clause, then reversed that exclusion on September 29, 2025 after a citizen petition and litigation, restating that NMN can be marketed as a dietary supplement. That reversal concerns NMN's supplement status specifically, not NAD+'s own (largely absent) compounding record.

References

  1. ClinicalTrials.gov. IV Administration of ChromaDex’s Niagen® as Compared to NAD+, NCT06382688. https://clinicaltrials.gov/study/NCT06382688
  2. Yu X, Xu J, Cao J, et al. Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial. Am J Cardiovasc Drugs. 2026;26(1):97–106. PMID 40954388. ChiCTR2200059169. https://pubmed.ncbi.nlm.nih.gov/40954388/
  3. Reyna K, Heinzen G, Patel N, Ritter M, Siojo A, Legere H, Pojednic R. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging. 2026;7:1652582. PMID 41704678. https://pubmed.ncbi.nlm.nih.gov/41704678/
  4. ClinicalTrials.gov. Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+, NCT06919328. https://clinicaltrials.gov/study/NCT06919328
  5. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

We may earn commissions from peptide vendor affiliate links.